Sunday, July 14, 2013

Patent Attorney, Seaton Currran to Speak at August 8th, 2013 NevBio Luncheon

Seaton Curran, J.D., MBA & P.E. of Howard & Howard will speak on 
"New Laws - New Strategy: How the Recent Changes in Patent Law Affect your IP Strategy", Thursday, August 8th, 11:30 am check-in, 12 lunch & talk, McCormick & Schmicks, $30. (Students & researchers are free)

This year, the most significant changes in patent law in over 50 years went into effect as the America Invents Act continues to be implemented.  As these new laws come into effect, businesses and inventors need to reevaluate their Intellectual Property strategies to adjust to the new changes.  The most significant change was implemented in March 16, 2013 when the Patent system changed from "First to invent" to "First Inventor to File".  Mr. Curran will discuss IP strategy and how the new patent laws affect the protection of your intellectual property.
  
Mr. Curran is an attorney with the law firm of Howard & Howard and concentrates his practice on intellectual property.  He advises clients in the development intellectual property strategies with a focus on maximizing business value through the protection and licensing of business assets.  He concentrates his practice in the area of patent law with experience in mechanical, electrical and computer software technologies, and assists client with the preparation and prosecution of U.S. and foreign patent applications, trademark registrations, patentability searches, patent landscape analysis, freedom-to-operate, infringement analyses and invalidity opinions.  Mr. Curran received his J.D. from the University of Nevada Las Vegas, M.B.A. from the University of Southern California, and BS in engineering from Loyola Marymount University.  He is licensed to practice in Nevada and before the USPTO, and holds a professional engineering license in Nevada.

Seaton Curran has presented to NevBio before. He gives an exceptional presentation. I would advise you not to miss his talk.
 
Sincerely,
 
John Laub
Nevada Biotechnology & Health Science Consortium
jlaub@regenmd.org

No comments: